drugset
drugset / Trial / NCT02266485

Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects

NCT02266485 ↗

Phase 1 Completed 60 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Investigation of pharmacodynamics (inhibition of oxidosqualene cyclase, MES as marker), effect on routine lipid profile parameters, safety and preliminary pharmacokinetics

Timeline

Start
1998-07
Primary completion
1998-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBB 515 BS Unknown 2.5 mg Oral
Comparator Pravastatin Small molecule 20 mg Oral

Indications

No indication recorded.